In the biopharmaceutical sector, the EVA-1 model realizes three levels of value output through the ArkAgentOS framework:
- Intelligent Document ProcessingThe PDF paper can be parsed simultaneously with text, molecular formula images and experimental data tables to automatically build a knowledge graph. Tests show that it takes only 4 hours to process a complete review of 200 papers, which is 18 times more efficient than manual work.
- Experimental design optimization: Integrating compound databases, clinical trial data, and patent information to provide researchers with synthetic pathway suggestions for candidate molecules, which was used by a CRO to shorten the lead compound screening cycle by 40%
- cross-modal inference: Unique multimodal understanding capability allows direct analysis of cryo-electron microscopy images for potential association with gene sequences, successfully assisting a team to discover the functional mechanism of a new variant of the GPCR receptor.
The platform now integrates more than 50 biopharmaceutical-specific intelligences, covering the entire process from target discovery to clinical trial design. Users can obtain structured analysis reports with literature citations by using natural language commands such as "Compare the differences in phase III clinical data of PD-1/PD-L1 inhibitors in non-small cell lung cancer".
This answer comes from the articleAutoArk: A Multi-Intelligence AI Platform that Collaborates on Complex TasksThe
May not be reproduced without permission:AI productivity tools " What are the specific application scenarios of the EVA-1 multimodal model in biopharmaceutical R&D?
English 
简体中文 
日本語 
Deutsch 
Português do Brasil